Anticoagulant Reversal

Product Monograph - Pradaxa® Reversal Agent

Overview • PRAXBIND is an immediate and specific reversal agent for PRADAXA • PRAXBIND is indicated in patients treated with PRADAXA when reversal of the anticoagulant effects of

  Product, Monographs, Anticoagulant, Product monograph, Reversal

Reversing the New Anticoagulants - UCSF CME

11/6/2013 2 Roadmap for today • Characteristics of novel anticoagulants • Approach to the bleeding patient • Specific reversal agents • UCSF guidelines Scope of Problem • Prevalence atrial fibrillation • 3.03 million in 2005 • 7.56 million by 2050 • VTE = 900K/yr in US • 1-2% of adults take warfarin Warfarin 1920s –Outbreak hemorrhagic disease in cattle in

  Anticoagulant, Reversing, Reversal, Reversing the new anticoagulants

NOAC GUIDELINES - NSW Health

noac guidelines non-vitamin k antagonist oral anticoagulant updated july 2017

  Guidelines, Anticoagulant, Noca, Noac guidelines

Anticoagulation in acute pulmonary embolism

Anticoagulation in acute pulmonary embolism

  Acute, Pulmonary, Embolism, Acute pulmonary embolism

DOAC At-a-Glance Reference updated: August 2018

erythromycin) avoided . P. reduction. Halflife: 5-9h . Tmax: 2-4h. NVAF . CrCl>50 mL/min 20mg daily with food AVOID concomitant P-gp and strong CYP3A4 inhibitors (ketoconazole,